Friday, 29th March 2024
To guardian.ng
Search
News  

U.K.-based analyst urges FG to fund researches, develop drugs to tackle diseases

A Nigerian U.K.-based Public Analyst, Mr Temi Kpogho, says adequate funding of researches into drugs and diseases by the Federal Government will enable scientists to proffer solutions. Kpogho, who made the assertion in an interview with the News Agency of Nigeria (NAN) in Lagos, said the pharmaceutical sector was an area that had been overlooked.…
Drugs- image source makingittv

Drugs- image source makingittv

A Nigerian U.K.-based Public Analyst, Mr Temi Kpogho, says adequate funding of researches into drugs and diseases by the Federal Government will enable scientists to proffer solutions.

Kpogho, who made the assertion in an interview with the News Agency of Nigeria (NAN) in Lagos, said the pharmaceutical sector was an area that had been overlooked.

He said that there were tropical diseases that needed to be tackled through locally developed drugs.

“Imagine what it will be for the country if the University of Ibadan is able to get funding to develop drugs for leading tropical diseases.

“The pharmaceutical sector is one huge area we have overlooked and there are tropical diseases we can develop drugs for to cater for Africa, South America, Asia and parts of the Middle East.

“There are a lot of ways our economy can be diversified if we can get the right people into public services.

“And our universities are funded to be centres of research not just teaching and graduating half-baked students,’’ Kpogho said.

The analyst said that in the U.K., there were lots of Bio-medical firms around Oxford and Cambridge Universities which were constantly conducting researches.

“Today, the pharmaceutical sector in the U.K. employs 27,000 people and exports over 14 billion pounds worth of products annually.

“But close to 4 billion pounds is spent annually on research and development,’’ Kpogho said.

He noted that pharmaceutical firms funded research into drugs and diseases in universities as a way of developing new products.

0 Comments